These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27046661)

  • 1. Rescue Therapy Using Rituximab for Multiple Sclerosis.
    Berenguer-Ruiz L; Sempere AP; Gimenez-Martinez J; Gabaldon-Torres L; Tahoces L; Sanchez-Perez R; Diaz-Marin C
    Clin Neuropharmacol; 2016; 39(4):178-81. PubMed ID: 27046661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
    Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
    Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in multiple sclerosis at general hospital level.
    Hellgren J; Risedal A; Källén K
    Acta Neurol Scand; 2020 Jun; 141(6):491-499. PubMed ID: 31990978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study.
    Yamout BI; El-Ayoubi NK; Nicolas J; El Kouzi Y; Khoury SJ; Zeineddine MM
    J Immunol Res; 2018; 2018():9084759. PubMed ID: 30539030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study.
    Zhao D; Zhao C; Lu J; Han Y; Sun T; Ren K; Ma C; Zhang C; Li H; Guo J
    Mult Scler Relat Disord; 2023 Feb; 70():104518. PubMed ID: 36657326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and fringe benefits of rituximab in multiple sclerosis treatment in a poor resource setting: Case series and cost analysis.
    Aungsumart S; Apiwattanakul M
    Mult Scler Relat Disord; 2023 May; 73():104673. PubMed ID: 37001410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
    Hu Y; Nie H; Yu HH; Qin C; Wu LJ; Tang ZP; Tian DS
    Autoimmun Rev; 2019 May; 18(5):542-548. PubMed ID: 30844555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective observational study of rituximab treatment in multiple sclerosis patients in Cyprus.
    Leonidou E; Pantzaris M; Kleopa KA; Loizidou MA; Kyriakides T; Christou YP
    Postgrad Med; 2019 Sep; 131(7):486-489. PubMed ID: 31353999
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
    Alcalá C; Gascón F; Pérez-Miralles F; Gil-Perotín S; Navarré A; Boscá I; Coret F; Casanova B
    J Neurol; 2018 Jul; 265(7):1690-1697. PubMed ID: 29785523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
    Rommer PS; Dörner T; Freivogel K; Haas J; Kieseier BC; Kümpfel T; Paul F; Proft F; Schulze-Koops H; Schmidt E; Wiendl H; Ziemann U; Zettl UK;
    J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis].
    Midaglia L; Mora L; Mulero P; Sastre-Garriga J; Montalban X
    Rev Neurol; 2018 Jan; 66(1):25-32. PubMed ID: 29251340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience.
    D'Amico E; Zanghì A; Chisari CG; Fermo SL; Toscano S; Arena S; Patti F; Zappia M
    Mult Scler Relat Disord; 2019 Jan; 27():324-326. PubMed ID: 30471585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab use in pediatric central demyelinating disease.
    Beres SJ; Graves J; Waubant E
    Pediatr Neurol; 2014 Jul; 51(1):114-8. PubMed ID: 24768216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.
    Stüve O; Leussink VI; Fröhlich R; Hemmer B; Hartung HP; Menge T; Kieseier BC
    Arch Neurol; 2009 Feb; 66(2):259-61. PubMed ID: 19204165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
    Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
    Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
    Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
    Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
    Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
    JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.